lu codes
Source: ODB Formulary/CDI, edition 43 (effective 2026-04-28). Unofficial search tool, checked weekly for updates.
/
showing 10 of 176 drugs (373 codes)
MIDODRINE HCL Amatine, Apo-Midodrine, Mar-Midodrine, Jamp Midodrine, Midodrine
For the treatment of patients disabled by moderate to severe neurogenic orthostatic hypotension (i.e. drop in systolic BP less than or equal to 20mm Hg from supine to standing position), in whom conventional nonpharmacologic and pharmacologic (i.e. fludrocortisone) therapies have proven ineffective or are poorly tolerated.
Indefinite
diuretics
IPRATROPIUM BROMIDE Atrovent, PMS-Ipratropium
For the treatment of non-allergic vasomotor rhinitis
1 year
other eye, ear, nose and throat agents
BOTULINUM TOXIN TYPE A Botox
For the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age or older.
1 year
For adult patients with urinary incontinence due to neurogenic detrusor overactivity resulting from neurogenic bladder associated with multiple sclerosis or subcervical spinal cord injury who fail to respond to behavioural medication and anticholinergics and/or are intolerant to anticholinergics.
1 year
The recommended dose is 200U injected into the detrusor muscle.
Subsequent injections should be provided at intervals of no less than every 36 weeks and patients who fail to respond to initial treatment with Botulinum Toxin Type A should not be retreated.
For adult patients with urinary frequency, urgency or urge incontinence due to overactive bladder who have:
1 year
Failed to respond to behavioral techniques AND had an inadequate response or intolerance to adequate trials (i.e., at least 2 weeks at the maximum tolerated dose) of at least two medications for overactive bladder (e.g. anticholinergics, mirabegron).
The recommended dose is 100U injected into the detrusor muscle.
NOTES:
-Patients who fail to achieve a reduction of greater than 50 percent in the frequency of urinary incontinence episodes with 1 dose should not be retreated.
-Maximum 3 doses per year in responders, at a frequency of no more than once every 12 weeks.
-Patients must have a post-void residual (PVR) urine volume of less than 150mL.
Note: Botox should be administered personally by a urologist, pediatrician, neurologist, physical medicine specialist or a physician with equivalent post-graduate training and experience with neuromuscular or urological disorders as appropriate.
CLOBAZAM Frisium, Teva-Clobazam, Apo-Clobazam
As adjunctive therapy in the treatment of seizure disorders where control by other listed anticonvulsants has been unsatisfactory.
Indefinite
Because a large number of patients will become refractory to the anticonvulsant effects of the drug over a period of time, the effectiveness of this drug must be re-evaluated after a period of six months.
anticonvulsants
FUROSEMIDE Lasix Special
For patients with severely impaired renal function refractory to conventional dosages of the drug.
Indefinite
diuretics
NIMODIPINE Nimotop
As adjunctive therapy to improve the neurologic outcome following subarachnoid haemorrhage during the acute management period (within 4 days of haemorrhage).
1 year
As prophylaxis of ischemia if surgery is delayed.
1 year
vasodilating drugs
DEXTRAN 70 & HYDROXYPROPYL METHYLCELLULOSE & POLYQUAD, PETROLATUM/MINERAL OIL, POLYVINYL ALCOHOL, POLYVINYL ALCOHOL & POLYVINYLPYRROLIDONE Tears Naturale II, Isopto Tears, Lacri-Lube, Soothe Night Time, Liquifilm Tears, Tears Plus
For patients with objective evidence of keratoconjunctivitis sicca as confirmed by filamentary keratopathy on slit lamp examination or biopsy.
Indefinite
other eye, ear, nose and throat agents
FLUNARIZINE HCL Sibelium, Flunarizine
For patients with migraine headaches who have not responded to propranolol.
1 year
For patients who have tried propranolol and experienced significant adverse effects.
1 year
For patients in whom propranolol is contraindicated.
1 year
Contraindicated in patients with clinical depression and in patients with extrapyramidal disorders.
LEVODOPA & CARBIDOPA Sinemet CR, AA-Levocarb CR
For patients with Parkinson's disease who have been treated with conventional therapy (Prolopa or conventional Sinemet), and experienced adverse effects related to drug level fluctuations, such as ON/OFF or wearing off phenomena.
Indefinite
For patients presently requiring anti-parkinsonian drug administration (levodopa/carbidopa) more than three times daily.
Indefinite
CARBAMAZEPINE Tegretol CR, Sandoz Carbamazepine CR
For patients who have been tried on conventional carbamazepine with unsatisfactory results due to adverse effects or poor control of symptoms.
Indefinite
anticonvulsants
No matching LU codes found.